# Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis

> **NCT01969409** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 58 (actual)

## Conditions studied

- Ambulatory IPF

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01969409
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2019-01-31
- **Final completion:** 2020-11-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01969409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01969409, "Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01969409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*